Magle Chemoswed Holding AB (publ) (STO: MAGLE)

Market Cap	706.63M
Revenue (ttm)	209.21M
Net Income (ttm)	16.75M
Shares Out	19.63M
EPS (ttm)	1.55
PE Ratio	23.22
Forward PE	17.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,111
Average Volume	1,847
Open	36.00
Previous Close	36.00
Day's Range	33.80 - 36.00
52-Week Range	24.40 - 49.80
Beta	0.56
RSI	46.69
Earnings Date	Feb 26, 2025

About STO: MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 78
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2023, MAGLE's revenue was 171.50 million, an increase of 15.89% compared to the previous year's 147.98 million. Earnings were 12.17 million, an increase of 33.07%.